WO2005118834A3 - Methods for identifying risk of breast cancer and treatment thereof - Google Patents

Methods for identifying risk of breast cancer and treatment thereof Download PDF

Info

Publication number
WO2005118834A3
WO2005118834A3 PCT/US2004/016940 US2004016940W WO2005118834A3 WO 2005118834 A3 WO2005118834 A3 WO 2005118834A3 US 2004016940 W US2004016940 W US 2004016940W WO 2005118834 A3 WO2005118834 A3 WO 2005118834A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
methods
treatment
identifying risk
subject
Prior art date
Application number
PCT/US2004/016940
Other languages
French (fr)
Other versions
WO2005118834A2 (en
Inventor
Richard B Roth
Matthew Roberts Nelson
Andreas Braun
Stefan M Kammerer
Rikard Reneland
Caridad Rosette
Mikhail F Denissenko
Jonas Goeran Ekblom
Carolyn R Hoyal-Wrightson
Original Assignee
Sequenom Inc
Richard B Roth
Matthew Roberts Nelson
Andreas Braun
Stefan M Kammerer
Rikard Reneland
Caridad Rosette
Mikhail F Denissenko
Jonas Goeran Ekblom
Carolyn R Hoyal-Wrightson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc, Richard B Roth, Matthew Roberts Nelson, Andreas Braun, Stefan M Kammerer, Rikard Reneland, Caridad Rosette, Mikhail F Denissenko, Jonas Goeran Ekblom, Carolyn R Hoyal-Wrightson filed Critical Sequenom Inc
Priority to PCT/US2004/016940 priority Critical patent/WO2005118834A2/en
Priority to CA002569100A priority patent/CA2569100A1/en
Priority to EP04753721A priority patent/EP1766041A2/en
Publication of WO2005118834A2 publication Critical patent/WO2005118834A2/en
Publication of WO2005118834A3 publication Critical patent/WO2005118834A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.
PCT/US2004/016940 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof WO2005118834A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/US2004/016940 WO2005118834A2 (en) 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof
CA002569100A CA2569100A1 (en) 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof
EP04753721A EP1766041A2 (en) 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/016940 WO2005118834A2 (en) 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof

Publications (2)

Publication Number Publication Date
WO2005118834A2 WO2005118834A2 (en) 2005-12-15
WO2005118834A3 true WO2005118834A3 (en) 2007-09-13

Family

ID=35463458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016940 WO2005118834A2 (en) 2004-05-27 2004-05-27 Methods for identifying risk of breast cancer and treatment thereof

Country Status (3)

Country Link
EP (1) EP1766041A2 (en)
CA (1) CA2569100A1 (en)
WO (1) WO2005118834A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734118A1 (en) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
WO2016094802A1 (en) * 2014-12-11 2016-06-16 Worcester Polytechnic Institute Characterization of pre-cancer biomarker for prognostic screen
US20190369100A1 (en) * 2017-01-14 2019-12-05 Nutech Ventures Mitochondrial protease oma1 as a marker for breast cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMMERER S. ET AL: "Association of the NuMa region on chromosome 11q13 with breast cancer suspectibility", PNAS, vol. 102, no. 6, 8 February 2005 (2005-02-08), pages 2004 - 2009, XP002988652 *
KAMMERER S. ET AL: "Large-Scale Association identifies ICAm gene region as breast and prostate cancer suspectibility locus", CANCER RESEARCH, vol. 64, 15 December 2004 (2004-12-15), pages 8906 - 8910, XP002988651 *

Also Published As

Publication number Publication date
EP1766041A2 (en) 2007-03-28
CA2569100A1 (en) 2005-12-15
WO2005118834A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
HK1116249A1 (en) B7-h1 and methods of diagnosis, prognosis, and treatment of cancer b7-h1
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
EP1888786A4 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
AU2003233451A8 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006034879A3 (en) Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
WO2005001141A3 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
ZA200703482B (en) B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005001140A3 (en) Methods and nucleic acids for the analysis of colon cell proliferative disorders
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2569100

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004753721

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004753721

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004753721

Country of ref document: EP